Velabs Therapeutics Raises EUR3 million to Advance Functional Antibody Screening Program
German-based company, Velabs Therapeutics, has closed its Series B financing round, raising EUR3 million (US$3.4 million).
German-based company, Velabs Therapeutics, has closed its Series B financing round, raising EUR3 million (US$3.4 million), it was revealed in a June 27, 2019 press release. The funding will be used by the company to advance its functional antibody screening program and to strengthen its pipeline of preclinical functional antibodies against disease with poor treatment options.
“This investment will enable us to advance the development of our own pipeline of preclinical functional antibodies and secure the expansion of our platform technology into new pharma-based co-development deals,” said Christoph Antz, managing director of Velabs in the press release.
“Further preclinical validation of our own antibody drug candidates against GPCRs and Ion Channels will enhance our position as a leader in the field of rapid functional antibody screening and development,” added Christoph Merten, scientific founder and CSO of Velabs.
Further details of the financing round were not disclosed.
Source: Velabs Therapeutics
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
